CRVS

Corvus Pharmaceuticals, Inc.

Contracts

Total Value

Stock Metrics

25.2%

Short % Float

22.5d to cover · High squeeze

88.7%

Inst % Float

10 holders · 2026-06-30

Orbimed Advisors L

Top Holder

8.5% of float

72.8M sh

Public Float

49/100

Dilution Score

Medium

15 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

49/100

MEDIUM

Inst: 88.71% · Top: Orbimed Advisors LLC.

Biotech Analytics

Oncology

32.89

Squeeze risk: HIGHBiotech Grade: F

Insider Buying0

Publications100

Dilution Risk49

Clinical Trials42

Short Interest70